Precision Wealth Strategies LLC Acquires Shares of 62,042 Aurinia Pharmaceuticals Inc $AUPH

Precision Wealth Strategies LLC bought a new stake in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 62,042 shares of the biotechnology company’s stock, valued at approximately $686,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. MAI Capital Management purchased a new stake in Aurinia Pharmaceuticals during the first quarter worth about $39,000. USA Financial Formulas bought a new position in shares of Aurinia Pharmaceuticals during the 3rd quarter valued at approximately $107,000. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Aurinia Pharmaceuticals during the 2nd quarter worth approximately $92,000. Bailard Inc. bought a new stake in shares of Aurinia Pharmaceuticals in the 2nd quarter worth approximately $99,000. Finally, Teza Capital Management LLC purchased a new position in Aurinia Pharmaceuticals in the first quarter valued at approximately $96,000. 36.83% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Leerink Partners downgraded Aurinia Pharmaceuticals from an “outperform” rating to a “market perform” rating and raised their target price for the stock from $15.00 to $16.00 in a research report on Wednesday, December 3rd. Leerink Partnrs lowered Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 3rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a report on Wednesday, October 8th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $15.00 target price (up previously from $9.00) on shares of Aurinia Pharmaceuticals in a research note on Wednesday, November 5th. Finally, Jefferies Financial Group raised shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their price target for the company from $10.00 to $21.00 in a research report on Friday, November 7th. Two analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, Aurinia Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $17.25.

Aurinia Pharmaceuticals Price Performance

Shares of NASDAQ:AUPH opened at $15.90 on Friday. The company’s fifty day moving average price is $14.77 and its 200-day moving average price is $11.97. The company has a debt-to-equity ratio of 0.15, a current ratio of 5.76 and a quick ratio of 5.17. The firm has a market capitalization of $2.10 billion, a price-to-earnings ratio of 28.39 and a beta of 1.42. Aurinia Pharmaceuticals Inc has a one year low of $6.55 and a one year high of $16.54.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its earnings results on Tuesday, November 4th. The biotechnology company reported $0.23 EPS for the quarter, beating analysts’ consensus estimates of $0.16 by $0.07. Aurinia Pharmaceuticals had a return on equity of 25.19% and a net margin of 29.28%.The business had revenue of $73.47 million for the quarter, compared to analysts’ expectations of $67.70 million. On average, equities research analysts anticipate that Aurinia Pharmaceuticals Inc will post 0.11 earnings per share for the current fiscal year.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.